Prodotti per terapia cellulare Pluristem a base di placenta

Pluristem Therapeutics Inc. (PSTI) (PSTI.TA),

uno sviluppatore leader di prodotti per la terapia cellulare a base di placenta, ha annunciato oggi che gli Stati Uniti. Amministrazione degli alimenti e dei farmaci (FDA) ha approvato la domanda di farmaco sperimentale di Pluristem (IND) for a Phase III study of its PLX-PAD cell therapy in the treatment of muscle injury following surgical repair (arthroplasty) of the hip joint due to fracture. Pluristem is in discussions with several EU countries to approve this study in Europe as well and expects to begin patient enrollment in both regions during 2018. Non-dilutive funding totaling $8.7 milioni (7.4 million Euro) has been granted to this study from Horizon 2020, the European Union’s largest research and innovation program.

The Phase III study follows positive results from a Phase I/II trial which demonstrated significant muscle regeneration when using PLX-PAD cells in total hip arthroplasty patients.

The study demonstrated a 300% change in muscle volume (p=0.004) and a 500% (p=0.0067) change in muscle force at 6 months post-surgery, compared to the control group.